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Immunotherapy is increasingly used in the treatment of glioblastoma (GBM), with
immune checkpoint therapy gaining in popularity given favorable outcomes achieved for
other tumors. However, immune-mediated (IM)-pseudoprogression is common, remains
poorly characterized, and renders conventional imaging of little utility when evaluating
for treatment response. We present the case of a 64-year-old man with GBM who
developed pathologically proven IM-pseudoprogression after initiation of a checkpoint
inhibitor, and who subsequently developed true tumor progression at a distant location.
Based on both qualitative and quantitative analysis, we demonstrate that an advanced
diffusion-weighted imaging (DWI) technique called restriction spectrum imaging (RSI)
can differentiate IM-pseudoprogression from true progression even when conventional
imaging, including standard DWI/apparent diffusion coefficient (ADC), is not informative.
These data complement existing literature supporting the ability of RSI to estimate
tumor cellularity, which may help to resolve complex diagnostic challenges such as the
identification of IM-pseudoprogression.
Keywords: brain tumors, restriction spectrum imaging, immunotherapy, pseudoprogression, diffusion imaging
BACKGROUND
In patients with GBM, surgical resection, followed by radiotherapy (XRT) with concomitant and
adjuvant temozolomide is the standard of care (1, 2). In up to 30% of patients, areas of new
or increasing enhancement and/or edema are seen on standard MRI within the radiation field
within the first few months following treatment (3). These findings mimic tumor progression;
however, they often resolve or stabilize without intervention. This phenomenon is referred to
as pseudoprogression. Although the underlying pathophysiology is unknown, it is thought to
represent treatment effect (3). In fact, patients who develop pseudoprogression have overall
improved survival rates (4). Due to the complexity of differentiating pseudoprogression from true
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progression, current guidelines established for evaluating
response to therapy in high-grade glioma [i.e., Response
Assessment in Neuro-oncology; RANO (5)] dictate that
progressive disease should not be diagnosed on imaging within
the first 3 months following completion of XRT unless there is:
(1) new enhancement outside the main radiation field or; (2)
pathologic confirmation of unequivocal tumor progression.
Recently, a new type of pseudoprogression has emerged,
further confounding the evaluation of treatment response in
patients with brain tumors. This type of pseudoprogression
follows treatment with immunotherapy. Immunotherapy is a
broad term which refers to several different types of therapeutic
agents, that target tumor cells by harnessing the patient’s own
immune system. These agents include checkpoint inhibitors,
vaccines, CAR-T therapy, and viral therapy (6). Following
treatment with immunotherapy, an immune reaction occurs
in the tumor bed with additional systemic effects throughout
the brain (7). As a result, areas of enhancement and edema
appear within and possibly distal to the primary tumor site.
As with standard pseudoprogression, immune-mediated (IM)-
pseudoprogression can mimic true tumor progression (8).
However, IM-pseudoprogression may occur later than standard
pseudoprogression and may occur distal to the primary site of
tumor (9). This has led to the development of the immune
RANO (iRANO) criteria (9). According to these criteria,
progressive disease should not be diagnosed on imaging within
the first 6 months following initiation of immunotherapy.
Given the profound implications for patient care, the ability
to differentiate true progression from IM-pseudoprogression is
of critical importance in Neuro-Oncology. Misdiagnosis could
potentially delay survival-prolonging treatments in patients with
true progression, while resulting in unnecessary surgical, or
medical interventions in patients with IM-pseudoprogression.
Conventional imaging alone has failed to differentiate IM-
pseudoprogression and true tumor progression, as both are
characterized by areas of increased contrast enhancement
and edema (10). To date, very few studies have utilized
advanced neuroimaging techniques to address the issue of IM-
pseudoprogression despite its increased recognition (11–13).
Among these, diffusion-weighted imaging (DWI) has generated
attention due to its proposed ability to provide a surrogate
marker of changes in tumor cellularity. However, it is well-
appreciated that DWI-derived apparent diffusion coefficient
(ADC) values are influenced by both edema and necrosis
within and surrounding the tumor bed. Because the immune
response may increase edema, lymphocytic infiltration, and
necrosis, the effects of these pathologies on the ADC signal
may reduce its ability to differentiate true progression from IM-
pseudoprogression.
An advanced DWImethod called restriction spectrum imaging
(RSI) has emerged as a promising new technique for estimating
tumor cellularity and has demonstrated initial efficacy for
evaluating treatment response in patients with GBM and other
high-grade gliomas (14). Unlike standard DWI, RSI utilizes
multiple b-values (b= 0, 500, 1,500, and 4,000 s/mm2 with 1, 6, 6,
and 15 unique gradient directions for each b-value, respectively)
and diffusion times to separate different components of
the diffusion signal, distinguishing the spherically-restricted
diffusion signal associated with tumor cellularity from hindered
diffusion signal that is influenced by edema and inflammation in
the extracellular matrix (15–18). Because the immune response
may increase edema, necrosis, and lymphocytic infiltration, we
tested whether RSI could offer an advantage for differentiating
true progression from IM-pseudoprogression.
We present a case of a patient with GBM who developed
IM-pseudoprogression after initiation of a checkpoint inhibitor.
This patient eventually developed true tumor progression at a
separate location. While both the IM-pseudoprogression and the
true tumor progression were characterized by regions of marked
contrast enhancement and edema, the two could be readily
distinguished using RSI, whereas differentiating these entities on
ADC was quite challenging.
CASE PRESENTATION
A 64-year-old male with no family history of cancer presented
with blurry vision in his right visual field, headache, and
difficulty with multitasking and writing. Initial MRI (3T GE
MR750 system) demonstrated a large enhancing mass in the
left temporal-occipital lobe. The patient underwent gross total
resection (GTR) (Figure 1, top row), and pathology showed
GBM, IDH-wild type (Ki-67 40%, MGMT unmethylated, EGFR
amplified). Following surgery, he received 6 weeks of radiation
(60 Gy/30 fractions) and concurrent temozolomide (TMZ; 140
mg/night). One month following completion of radiation, he
began therapy with a checkpoint inhibitor (nivolumab 240mg
IVq 2 weeks). Three months following initiation of nivolumab,
the patient developed an area of heterogeneous enhancement
around the surgical cavity with new confluent surrounding
FLAIR hyperintensity (Figure 1, middle row). Whereas, the
ADC was equivocal, there was no elevated signal on RSI or
increased relative cerebral blood volume (rCBV) on dynamic
susceptibility contrast (DSC) perfusion MRI. The patient had
no changes in his clinical symptoms. Despite this, due to
suspicion of tumor progression, the patient underwent a second
resection. Histopathology revealed a lesion with abundant foamy
macrophages in addition to a mixed chronic inflammatory
infiltrate, neutrophils, and fragments of neutrophilic debris.
Foci of geographic coagulative necrosis, attributed to radiation
effect were also observed (Figures 2A–C). However, no viable
tumor cells were detected, supporting a diagnosis of IM-
pseudoprogression. Three months later, following treatment with
nivolumab, the patient became dysarthric and his concentration
and handwriting worsened. MRI revealed a new distant region
of enhancement and FLAIR hyperintensity in the left posterior
frontal lobe (Figure 1, bottom row), this time associated with
elevated signal on RSI and increased rCBV. Although ADC did
demonstrate subtle low signal at the site of enhancement at the
time of true progression, this signal is very similar to that of
the normal appearing white matter, while the elevated RSI signal
within this region is muchmore conspicuous (see Figure 1; white
arrows). The region was biopsied, and pathology showed highly
cellular, moderately pleomorphic tumor cells with brisk mitotic
activity and regions of serpiginous pseudopallisading necrosis.
These findings confirmed recurrent GBM (Figures 2D–F). The
area of IM-pseudoprogression at the original surgery site had
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FIGURE 1 | Multiparametric imaging of a patient with GBM at baseline (after 6 weeks of chemoradiation; top row), 3 months after initiation of nivolumab (middle row),
and after another 3 months (bottom row). White arrows depict the regions of true tumor progression on ADC and RSI-CM. All images were acquired on a 3T GE
MR750 system. RSI-CM, restriction spectrum imaging cellularity map.
FIGURE 2 | The top panels (A–C) are from the IM pseudoprogression time-point, demonstrating paucicellular, mitotically quiescent tissue whereas the bottom panels
(D–F) are from the true progression time-point demonstrating glioblastoma. The IM pseudoprogression lesion contains abundant foamy macrophages (A) in addition
to a mixed chronic inflammatory infiltrate (B). Some regions also show neutrophils and fragments of neutrophilic debris (insert B). Foci of geographic coagulative
necrosis, attributable to radiation effect, are also present (C). The glioblastoma shows highly cellular, moderately pleomorphic, predominantly spindle-shaped tumor
cells (D) with brisk mitotic activity (arrowheads E) and regions of serpiginous pseudopallisading necrosis (F). Magnification of the images is as follow: (C,F × 100.
A,B,D × 200. E,B × 400). All images are taken from hematoxylin and eosin stained, formalin-fixed paraffin-embedded tissue.
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FIGURE 3 | RSI (top row) and ADC (bottom row) histograms extracted from volumes manually defined by FLAIR hyperintensity (left column) and contrast
enhancement (right column). The y-axis represents frequencies and the x-axis represents intensity values within each volume. PsP, pseudoprogression; TP, true
progression; RSI, restriction spectrum imaging cellularity; ADC, apparent diffusion coefficient.
resolved in the interim. Thereafter, there were no further imaging
changes at this site.
Quantification of the RSI and ADC signals within regions
of contrast-enhancement and FLAIR hyperintensity were
performed to further support our visual analysis (Figure 3).
Inspection of RSI signal intensity histograms in Figure 3 (top
row) reveals peak frequencies that are much higher for true
progression relative to IM-pseudoprogression and mostly non-
overlapping intensity distributions in volumes defined by both
contrast enhancement and FLAIR hyperintensity. Conversely,
there is considerable overlap in the peaks and distribution
of values for ADC in both contrast-enhancing and FLAIR
hyperintense regions (Figure 3; bottom row), resulting in poor
differentiation of true progression and IM-pseudoprogression.
This is especially salient within the contrast-enhancing region
where the mean RSI signal is higher for true progression (mean
intensity= 1.00) than for IM-pseudoprogression (mean intensity
= 0.89), whereas the ADC values within the contrast-enhancing
region are nearly identical for true progression (mean intensity
= 0.98), and IM-pseudoprogression (mean intensity= 0.97).
DISCUSSION
RSI is an advanced DWI technique that has been shown
to improve tumor conspicuity in patients with high-grade
glioma (16) and provide a better biomarker of response
to therapy in patients on antiangiogenic agents, relative to
standard DWI (17, 18). Furthermore, our previous work has
shown that RSI estimates of cellularity are directly related to
histopathological tumor cellularity in preclinical models (15,
19). The case presented here demonstrates that RSI may also
be a promising tool for differentiating IM-pseudoprogression
from true progression, potentially by isolating the restricted
diffusion associated with cellularity and removing the hindered
signal associated with edema, lymphocytic infiltration, and
necrosis. This property of RSI provides an advantage over
standard ADC, which is often dominated by changes in hindered
diffusion (16). In fact, in a series of 21 children treated with
a peptide-based vaccine for diffuse pontine gliomas, changes
in ADC only modestly differentiated true progression from
IM-pseudoprogression (12). The authors acknowledged that
suboptimal differentiation was likely due to the inability of
ADC to distinguish viable tumor (low ADC) from necrosis and
vasogenic edema (high ADC). Thus, when measuring changes
in ADC, the lower ADC values of a viable tumor likely blend
in with the higher ADC values found in areas of necrosis and
edema (see Figure 1; bottom row). As a result, current ADC
models do not sufficiently meet the challenge posed by IM-
pseudoprogression.
The case presented here demonstrates that RSI is able to
differentiate pathologically proven IM-pseudoprogression from
true progression in the same patient. This is supported by
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both visual inspection and quantification of the RSI cellularity
maps. Whereas, the visual analysis is critical for making
individual diagnostic decisions, quantification of the RSI signal
could be used to differentiate IM-pseudoprogression from true
progression in clinical trials and/or when visual inspection is
equivocal. In terms of feasibility, RSI has already been seamlessly
integrated into the clinical workflow at our center as well as
several others. The sequence takes ∼4min on most 3T MRI
systems, is post-processed on a separate workstation within
∼5min of completion of the scan, and the post-processed RSI
map is then sent back to PACS as the final series of the MRI
scan. Furthermore, the clinical interpretation of the RSI map is
analogous to that of DWI, albeit with greater conspicuity and
specificity, making the output highly familiar to radiologists.
It is important to note that in our case the RSI signal was
concordant with results from DSC-MRI at both time-points.
Thus, RSI-based measures of cellularity provide complementary
information to rCBV, and therefore may be used in combination
with perfusion imaging to increase confidence in diagnosing IM-
pseudoprogression.
In addition to immunotherapy, our patient received
standard chemoradiation with evidence of radiation effect
on histopathology. Therefore, it is important to consider
that the pseudoprogression observed in our patient may
reflect a combination of standard chemoradiation and
immunotherapy. However, the presence of inflammatory
cells on histopathology and the timing of the MRI changes
(>3 months following chemoradiation) increases the likelihood
of IM-pseudoprogression. This case demonstrates that RSI
could be used to prevent unnecessary biopsy or surgical
interventions in the case of pseudoprogression in patients
treated with immunotherapy.
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